Idarubicin-anti-CD3: A new immunoconjugate that induces alloantigen- specific tolerance in mice

Transplantation

Volumn 64, Issue 5, 1997, Pages 684-690

  Mottram, Patricia L ^b   Han, Wen Ruo ^b   Murray Segal, Lisa J ^b   Mandel, Thomas E ^b   Pietersz, Geoffrey A ^a   McKenzie, Ian F C ^a  

^a AUSTIN RESEARCH INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIBODY CONJUGATE; CD3 ANTIGEN; IDANORUBICIN MONOCLONAL ANTIBODY CONJUGATE; IDARUBICIN; IDARUBICIN MONOCLONAL ANTIBODY CONJUGATE; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; FLUOROMETRY; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN GRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; CELL DIVISION; EPITOPES; GRAFT SURVIVAL; HEART TRANSPLANTATION; IDARUBICIN; IMMUNE TOLERANCE; IMMUNOCONJUGATES; ISOANTIGENS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, INBRED CBA; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030961154     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199709150-00004     Document Type: Article

References (39)

1. Ehrlich P. The relationship existing between chemical constitution, distribution, and pharmacological action. In: Himmelweite IF, Marquardt M, Dale H, eds. The collected papers of Paul Ehrlich, vol 1. Tarrytown, NY: Pergamon Press, 1956: 596.
2. Vitetta ES, Thorpe PE, Uhr JW. Immunotoxins: magic bullets or misguided missiles? Immunol Today 1993; 14: 252.
3. Vallera DA. Immunotoxins: will their clinical promise be fulfilled? Blood 1994; 83: 309.
4. Pietersz GA. The use of drug-antibody conjugates for the treatment of cancer. Cancer Forum 1993; 17: 116.
5. McKenzie IF, Smyth M, Mottram P, Bogdanovski M, Pietersz GA. Monoclonal antibody-drug/toxin immunoconjugates in transplantation. Transplant Proc 1989; 21 (1 Pt 1): 823.
6. Crooke ST, Duverney VH, Mong S. Molecular pharmacology of anthracyclines. In: Sartorelli CA, Lazo JS, Bertino JR, eds. Molecular actions and targets for cancer chemotherapeutic agents. New York: Academic Press, 1981: 137.
7. Mottram PL, Purcell LJ, Pietersz GA, McKenzie IF. Tolerance induction with anti-CD8 monoclonal antibodies in the mouse heart transplant model. Transplant Proc 1993; 25: 2935.
8. Leo O, Foo M, Sachs DH, Samelson LE, Bluestone JA. Identification of a monoclonal antibody specific for a murine T3 polypeptide. Proc Natl Acad Sci USA 1987; 84: 1374.
9. Kung PC, Goldstein G, Reinherz EL, Schlossman SF. Monoclonal antibodies define distinctive human T cell surface antigens. Science 1979; 206: 347.
10. Nicolls MR, Aversa GG, Pearce NW, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993; 55: 459.
11. Roitt IM. OKT3: immunology, production and pharmacokinetics. Clin Transplant 1993; 7: 367.
12. Kreis H. Adverse effects associated with OKT3 immunosuppression in the prevention or treatment of allograft rejection. Clin Transplant 1993; 7: 431.
13. Mandel TE, Koulmanda M. Anti-T cell monoclonal antibodies for immunosuppression in xenotransplantation of fetal pig pancreas in NOD mice. Transplant Proc 1993; 25 (1 Pt 1): 796.
14. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci USA 1994; 91: 123.
15. Tomonari K. A rat antibody against a structure functionally related to the mouse T-cell receptor/T3 complex. Immunogenetics 1988; 28: 455.
16. Potter M. Immunoglobulin-producing tumors and myeloma proteins of mice. Physiol Rev 1972; 52: 631.
17. Pietersz GA, Smyth MJ, McKenzie IFC. Immunochemotherapy of a murine thymoma with the use of idarubicin-monoclonal antibody conjugates. Cancer Res 1988; 48: 926.
18. Hogarth MC, Henning MM, McKenzie IFC. Alloantigenic phenotype of radiation induced thymomas in the mouse. J Natl Cancer Inst 1982; 69: 619.
19. Mottram PL, Purcell LJ, Kalina SL. Microsurgical techniques for transplantation of vascularised organs in mice. In: Green MK, Mandel TE, eds. Experimental transplantation models in small animals. Melbourne, Australia: Gordon and Breach Science Publishers, 1995: 175.
20. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice: the role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973; 16: 343.
21. Mottram PL, Smith JA, Mason A, Mirisklavos A, Dumble LJ, Clunie GJ. Electrocardiographic monitoring of cardiac transplants in mice. Cardiovasc Res 1988; 22: 315.
22. Billingham R, Medewar P. Technique of free skin grafting in mammals. J Exp Biol 1951; 28: 385.
23. Mackie JD, Pankewycz OG, Bastos MG, Kelley VE, Strom TB. Dose-related mechanisms of immunosuppression mediated by murine anti-CD3 monoclonal antibody in pancreatic islet cell transplantation and delayed-type hypersensitivity. Transplantation 1990; 49: 1150.
24. Alegre M, Vandenabeele P, Flamand V, et al. Hypothermia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. Eur J Immunol 1990; 20: 707.
25. Ferran C, Sheehan K, Dy M, et al. Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur J Immunol 1990; 20: 509.
26. Mottram PL, Pietersz GA, Purcell LJ, Krauer K, Clunie GJ, McKenzie IF. Deletion of graft reactive cells by idarubicin-anti-CD8 (Ly-2.1) immunoconjugate: studies in the mouse heart graft model. Transplant Proc 1991; 23 (1 Pt 1): 499.
27. Mottram PL, Smyth M, Pietersz GA, Clunie GJ, McKenzie IF. Anti-T cell-specific immunoconjugates in mice: in vivo effects. Transplant Proc 1989; 21: 3757.
28. Cobbold SP, Qin S, Leong LYW, Martin G, Waldmann H. Reprogramming the immune system for peripheral tolerance with CD4 and CD8 monoclonal antibodies. Immunol Rev 1992; 129: 164.
29. Chen Z, Cobbold SP, Metcalfe S, Waldmann H. Tolerance in the mouse to major histocompatibility complex-mismatched heart allografts and to rat xenografts, using monoclonal antibodies to CD4 and CD8. Eur J Immunol 1992; 22: 805.
30. Mottram PL, Wheelahan J, Mirisklavos A, Clunie GJ, McKenzie IF. Prolongation of murine cardiac allografts following treatment of graft recipients with monoclonal anti-L3T4 and Ly-2 antibodies. Transplant Proc 1987; 19 (1 Pt 1): 582.
31. Pearson TC, Darby CR, Bushell AR, West LJ, Morris PJ, Wood KJ. The assessment of transplantation tolerance induced by anti-CD4 monoclonal antibody in the murine model. Transplantation 1993; 55: 361.
32. Braun WE, Popowniak KL, Nakamoto S, Gifford RW, Stafford RA. The fate of renal allografts functioning for a minimum of 20 years (level 5A): indefinite survival or the beginning of the end? Transplantation 1995; 60: 784.
33. Starzl TE, Demitris AJ, Trucco M, et al. Chimerism and donor- specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation 1993; 55: 1272.
34. Hall BM. Cells mediating allograft rejection. Transplantation 1991; 51: 1141.
35. Qin S, Cobbold SP, Pope H, et al. Infectious transplantation tolerance. Science 1993; 259: 974.
36. MacLean JA, Su Z, Colvin RB, Wong JT. Anti-CD3:anti-IL-2 receptor-bispecific mAb-mediated immunomodulation. Low systemic toxicity, differential effect on lymphoid tissue, and inhibition of cell-mediated hypersensitivity. J Immunol 1995; 155: 3674.
37. Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects. Transplantation 1993; 55: 901.
38. Mandel TE, Koulmanda M. Effect of immunosuppression with anti-T-cell monoclonal antibodies on the survival of organ-cultured fetal pig pancreas xenografts in nonobese diabetic mice. Transplant Proc 1993; 25: 2926.
39. Mottram PL, Han WR, Purcell LJ, McKenzie IF, Hancock WW. Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. Transplantation 1995; 59: 559.